<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Enveric Biosciences ( (ENVB) ). On April 14, 2026, Enveric Biosciences filed its definitive proxy statement for the May 28, 2026 virtual annual meeting, seeking shareholder votes on electing six directors, an advisory say-on-pay resolution, a reverse stock split authorization in a 1-for-5 to 1-for-15 range, a major increase in authorized common shares to 5 billion, auditor ratification for 2026, and potential adjournment authority. After discovering that some proxy materials mistakenly described the reverse split range as 1-for-5 to 1-for-50, the company filed supplemental proxy materials on April 30, 2026 to correct the maximum split ratio to 1-for-15 while confirming that all other proposals, meeting logistics, and the record date remain unchanged, signaling continued efforts to maintain listing flexibility and capital-raising capacity while ensuring clarity for shareholders ahead of key structural votes. Spark’s Take on ENVB Stock According to Spark, TipRanks’ AI Analyst, ENVB is a Neutral. The score is held down primarily by weak financial performance (no revenue, persistent losses, and continued cash burn), only partly offset by a low-debt balance sheet. Technicals are supportive in the short term with price above major shorter-term moving averages, but RSI indicates momentum is stretched. Valuation remains constrained by ongoing losses and the lack of a dividend yield. To see Spark’s full report on ENVB stock, click here. More about Enveric Biosciences Enveric Biosciences, Inc. is a biotechnology company focused on developing innovative treatments, operating within the life sciences and pharmaceutical sector. The company targets medical markets that benefit from novel therapeutics and depends on access to public equity markets, making its capital structure and corporate governance decisions significant for investors. Average Trading Volume: 4,096,914 Technical Sentiment Signal: Sell Current Market Cap: $10.25M Learn more about ENVB stock on TipRanks’ Stock Analysis page.</div>

ENVB

SBIO

LABU

Enveric Biosciences (ENVB) filed a corrected proxy statement for its May 28, 2026, annual meeting, clarifying the reverse stock split range from 1-for-50 to 1-for-15. The meeting will also address the election of six directors, an advisory say-on-pay resolution, and a significant increase in authorized shares to 5 billion. Despite a neutral rating from Spark due to weak financial performance, the company aims to maintain listing flexibility and capital-raising capacity. ENVB's current market cap is $10.25M, with ongoing losses impacting valuation.

Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure